NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
STALEVO 75 (carbidopa, levodopa, and entacapone) by Orion Pharma is dopa decarboxylase inhibitors [moa]. Approved for aromatic amino acid decarboxylation inhibitor [epc]. First approved in 2003.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 75 is a fixed-dose combination tablet containing carbidopa, levodopa, and entacapone, approved in 2003 for Parkinson's disease. It works by inhibiting DOPA decarboxylase and extending levodopa availability in the brain, reducing motor fluctuations in patients with advanced disease. The combination approach addresses the need for more stable dopaminergic stimulation throughout the day.
$0.018BPart D
LOE ApproachingWith LOE approaching and modest Part D spending ($18K), STALEVO 75 represents a niche product with declining team investment and limited growth opportunities.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications (1)
Clinical Trials (1)
Levodopa Concentration Profile With Stalevo 75/125 mg
Started Dec 2009
20 enrolled
Parkinson's Disease
Career Relevance
With zero linked job postings and LOE approaching, STALEVO 75 represents a declining career opportunity with limited growth trajectory. Professionals seeking stability and established product knowledge may find value, but those pursuing dynamic growth should consider earlier-lifecycle products.
Worked on STALEVO 75 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.